REVIEW article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1613199
The Use of Granulocyte Colony-Stimulating Factors (G-CSFs) in the Management of Breast Cancer Patients
Provisionally accepted
- Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Masovian, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The dynamic development of oncology poses new challenges to health care practitioners (HCPs), related to the introduction of modern targeted therapies, immunotherapies, or new chemotherapy regimens. The previous treatment algorithm for neutropenia and febrile neutropenia have significantly reduced the frequency of these complications in long-term therapies. Currently, breast cancer (BC) treatment is also based on the use of modern therapies, showing different toxicity profile. This article discusses the role of granulocyte colony-stimulating factors (G-CSFs) in wellknown and new therapies used in the treatment of breast cancer patients. The factors influencing the development of hematological complications such as neutropenia and febrile neutropenia were presented. An important aspect of the assessment of patients at increased risk of therapy-induced toxicity was discussed with highlighting the fact that the treatment regimen is not the only factor influencing the development of adverse events (AEs). The aim of the study is to consolidate recommendations for the primary and secondary prevention of neutropenia and febrile neutropenia and related improvement of treatment outcomes in patients with BC.
Keywords: AC -doxorubicin, cyclophosphamide breast cancer, Neutropenia, Febrile neutropenia, Granulocyte colony-stimulating factors, Filgrastim, Pegfilgrastim, anticancer therapy toxicity
Received: 16 Apr 2025; Accepted: 29 Jul 2025.
Copyright: © 2025 Balata, Szombara, Nowecki and Pogoda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Anna Balata, Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, 02-781, Masovian, Poland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.